Which of the following markers increases the risk of recurrent carcinoma breast?
**Question:** Which of the following markers increases the risk of recurrent carcinoma breast?
A. Estrogen Receptor (ER)
B. Progesterone Receptor (PR)
C. Human Epidermal Growth Factor Receptor 2 (HER2)
D. Ki-67 Proliferation Index
**Core Concept:** Markers in breast cancer prognosis refer to various proteins, receptors, and genes that can help assess the likelihood of cancer recurrence and patient survival. These markers are essential in determining treatment strategies, such as hormone therapy or targeted therapy.
**Why the Correct Answer is Right:** Ki-67 Proliferation Index (also known as MIB-1) is a marker that reflects the rate of cell division in cancer cells. A high Ki-67 index indicates a more aggressive tumor and increased risk of recurrence. This marker is particularly important in early-stage breast cancer patients who are candidates for adjuvant therapy.
**Why Each Wrong Option is Incorrect:**
A. Estrogen Receptor (ER): ER is a protein that binds to estrogen and plays a role in breast cancer growth. A positive ER status indicates that the cancer cells can be influenced by estrogen therapy, which reduces the risk of recurrence.
B. Progesterone Receptor (PR): Similar to ER, PR is a protein that binds to progesterone and is involved in breast cancer growth. A positive PR status indicates that the cancer cells can be influenced by progesterone therapy, reducing the risk of recurrence.
C. Human Epidermal Growth Factor Receptor 2 (HER2): HER2 is a protein that promotes cell growth. Overexpression or amplification of HER2 increases the risk of breast cancer recurrence and poor prognosis.
D. Ki-67 Proliferation Index: As mentioned earlier, high Ki-67 index indicates increased cell division and a higher risk of recurrence.
**Clinical Pearl:** In breast cancer prognosis, a combination of ER, PR, HER2, and Ki-67 status is crucial for accurate risk assessment and treatment planning. A thorough evaluation of these markers is essential for determining the most effective therapy and predicting patient outcomes.